ICE2 (Iceni Pharmaceuticals)(ICE2 (Iceni Pharmaceuticals))

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Iceni Pharmaceuticals Ltd

在研机构

Iceni Pharmaceuticals Ltd

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 ICE2 (Iceni Pharmaceuticals) 相关的临床结果

登录后查看更多信息

100 项与 ICE2 (Iceni Pharmaceuticals) 相关的转化医学

登录后查看更多信息

100 项与 ICE2 (Iceni Pharmaceuticals) 相关的专利（医药）

登录后查看更多信息

2

项与 ICE2 (Iceni Pharmaceuticals) 相关的文献（医药）

2022-01-01·Therapeutic advances in ophthalmology

A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants

Article

作者: Ratnarajan, Gokulan ; Jones, Lee ; Qidwai, Umair

Background::

Minimally invasive glaucoma surgery (MIGS), including minimally invasive bleb surgery (MIBS), is a rapidly evolving area of research and clinical interest in ophthalmology. The growing number of devices has necessitated evaluations to identify subtle differences in outcomes between treatments.

Objectives::

To compare clinical effectiveness and safety outcomes of iStent combined with endoscopic cyclophotocoagulation (ICE2) with bleb forming PreserFlo MicroShunt (PMS) and XEN-45 gel implant in a 24-month retrospective review.

Design::

A retrospective review of patient records.

Methods::

We compared outcomes of 247 patients undergoing one of three glaucoma procedures (ICE2 = 162; PMS = 48; XEN-45 = 37) at a single facility in the United Kingdom. Clinical records were reviewed retrospectively between July 2016 and May 2020. Pairwise comparisons and within group analyses were performed to assess intraocular pressure (IOP), best-corrected LogMAR visual acuity (BCVA), the Humphrey visual fields and antiglaucoma medication outcomes across the three treatment groups.

Results::

No statistically significantly differences in IOP between the groups at day 7, 6 months, 12 months and 24 months. PMS had statistically significantly change in IOP between baseline and day 7 compared with ICE2 ( p = 0.003). BCVA was statistically significant different at 24 months between the ICE2 compared with PMS group (0.12 versus 0.33 LogMAR; p = 0.002). PMS group achieved the largest decline in medication usage between baseline a 24-month follow-up (2.9 versus 0.9; p < 0.001), with no statistically significant difference in the number of antiglaucoma medications being used between groups at 24 months. Postoperative complications in all three groups were transient and could be resolved with office-based interventions.

Conclusion::

Real-world outcomes after 24 months were similar between patients undergoing MIGS and MIBS procedures.

2020-10-01·The British journal of ophthalmology2区 · 医学

Outcomes of phacoemulsification combined with two iStent inject trabecular microbypass stents with or without endocyclophotocoagulation

2区 · 医学

Article

作者: Pantalon, Anca Delia ; Ratnarajan, Gokulan ; Barata, Andre Diogo De Oliveira ; Georgopoulos, Minas

Aim:

Comparing outcomes after combined phacoemulsification, two iStents insertion and endocyclophotocoagulation (ECP) versus phacoemulsification-iStents alone.

Methods:

This is a longitudinal retrospective 12 months study in eyes with ocular hypertension or early-to-moderate open angle glaucoma. Level of disease, intraocular pressure (IOP) and tolerance of glaucoma medication were considered before planning surgery. Best-corrected visual acuity (BCVA-logMAR), IOP (mm Hg), number of medications were assessed at baseline, week 1, week 5, month 3, 6, 12 postop. Main outcome: percentage (%) in IOP reduction at 12 months vs medicated baseline. Secondary outcomes: absolute values of IOP/medication reduction, BCVA and postop complications.

Results:

The ICE2 (two iStents-cataract extraction-ECP) group included 63 eyes and Phaco-iStent group included 46 eyes. Baseline IOP was higher in the ICE2 than phaco-iStent group (19.97±4.31 mm Hg vs 17.63±3.86 mm Hg, p=0.004) and mean deviation was lower (−7.20±2.58 dB vs −4.94±4.51 dB, p=0.037). Number of medications were comparable at baseline: 2.22±1.06 (ICE2) vs 2.07±1.02 (phaco-iStent), p=0.442. At month 12 postop, IOP in the ICE2 group decreased 35% from baseline vs 21% in the phaco-iStent group (p=0.03); absolute IOP reduction was significantly lower than baseline in each group (p<0.001), yet final IOP was lower in the ICE2 group than phaco-iStent group (13.05±2.18 mm Hg vs 14.09±1.86 mm Hg, p=0.01). Similar results were found for glaucoma medication (1.24±1.05 in ICE2 group vs 1.39±1.03 in phaco-iStent group, p=0.01). Final BCVA was 0.11±0.18 (phaco-iStent group) vs 0.08±0.08 (ICE2 group), p=0.309. Safety outcomes were comparable between groups.

Conclusion:

ICE2 procedure offers better results in IOP/medication reduction at 12 months than phacoemulsification-iStents alone.

100 项与 ICE2 (Iceni Pharmaceuticals) 相关的药物交易

登录后查看更多信息